NC410 in combination with Pembrolizumab enrolling participants with advanced unresectable and/or metastatic solid tumors including CRC, Gastric including GE junction, Esophageal, Ovarian, and H&N cancers regardless of prior treatment with ICIs or MSS/MSI status.
NC410 will be given intravenously (IV) every 2 weeks
Pembrolizumab 400mg will be given IV every 6 weeks.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.